Neuberger Berman's portfolio manager buys $111,604 in common stock

Neuberger Berman High Yield Strategies Fund (NHS) Portfolio Manager Chris Kocinski recently purchased 15,000 shares of NHS at an average price of $7.4403, totaling approximately $111,604. This purchase comes as NHS maintains a 14.5% dividend yield and a P/E ratio of 6, while also announcing a monthly distribution of $0.0905 per share, though the distribution's source may include net investment income, realized capital gains, and a return of capital. InvestingPro analysis suggests NHS may be undervalued, highlighting potential opportunities for investors.

Analysis

A Portfolio Manager at Neuberger Berman High Yield Strategies Fund Inc. (NHS), Chris Kocinski, recently acquired 15,000 shares of the fund's common stock at an average price of $7.4403 per share, a transaction totaling approximately $111,604, which now constitutes his entire direct holding. This insider purchase occurs for a fund with a $226 million market capitalization that reports a significant 14.5% dividend yield, a track record of 17 consecutive years of dividend payments, and currently trades at a P/E ratio of 6. NHS has also announced its regular monthly distribution of $0.0905 per share, adhering to its level distribution policy; however, it's important to note that these distributions can consist of net investment income, realized capital gains, or a return of capital, with the precise sourcing and tax implications determined post year-end. The parent company, Neuberger Berman, manages $515 billion in assets. External analysis from InvestingPro further suggests NHS may be undervalued, adding a layer of potential opportunity for the discerning investor, supported by a strongly positive sentiment score of 0.65 for the news and an even higher per-ticker sentiment of 0.85 for NHS.

Key Decisions for Investors

• The substantial insider purchase by the Portfolio Manager may be interpreted as a bullish signal, suggesting confidence in the fund's valuation and future prospects.
• Investors should evaluate the attractive 14.5% dividend yield and low P/E ratio of 6 in conjunction with the fund's level distribution policy, paying close attention to the composition of distributions to understand the sustainability of the yield, especially the potential for return of capital.
• Given the InvestingPro analysis indicating potential undervaluation and the fund's consistent dividend history, investors might consider conducting further due diligence on NHS's underlying holdings and income generation capacity before initiating or adjusting positions.